Cannatrek, a leader in the Australian medicinal cannabis industry, has made an impressive mark by securing the second spot on the Australian Financial Review’s Fast 100 List for 2023. This notable achievement follows a year of substantial growth, with the company nearly doubling its revenue to almost $90 million. Tommy Huppert, the CEO and founder of Cannatrek, credits this success to the company’s dedication to making plant-based medicines both affordable and accessible for eligible patients.
The company has seen a swift increase in revenue, profit and patient numbers, maintaining more than two consecutive years of monthly profits. This growth trajectory highlights Cannatrek’s effective strategy and commitment to meeting the growing demand for medicinal cannabis.
With approximately 900 shareholders and a workforce of 130 employees, Cannatrek is strategically positioning itself for sustained growth.
The company’s success in the AFR Fast 100 List not only reflects its financial achievements but also underscores its role in shaping the future of medicinal cannabis treatment and accessibility in the country.
Information about studies provided by Cannatrek on this website is for education purposes only. It is not a substitute for professional health advice. Nothing contained in this site, or any external site linked to by Cannatrek, is intended to be used as medical advice and it is not intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for your own health professional’s advice. Cannatrek does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information provided on this website, or any external site linked to by Cannatrek. Further, Cannatrek accepts no responsibility for material contained in a website that is linked to this site. It is the responsibility of the user to make their own decisions about the accuracy, currency, reliability and correctness of information contained in linked external websites.
